Monday, September 14, 2026

Korea’s WWII Victims Lose Appeal: What This Means for Compensation Claims

The Seoul High Court rejects a lawsuit for compensation from the Korea-Japan Agreement, urging legislative action for victims' support.

This AI Learns to Stay in Control—UNIST Retains 90% Performance in Unfamiliar Conditions

UNIST's research team developed a new reinforcement learning technique that ensures stable performance in changing environments, enhancing AI resilience.

Ripple Faces a Steep 6% Drop, Bitcoin Holds Steady Amid Crypto Market Struggles

Ripple's value dropped over 6% to $2.36 amid market pressures, causing its ranking to fall from third to fourth place.

Tag: immuno-oncology

North KoreaKoreaKimMilitaryAISouth Koreamarketrelationsdevelopment

AbClon Secures Japanese Patent for Dual-Antibody Cancer Drug AM105: What This Means for Global Markets

AbClon has completed the registration of a Japanese patent for its next-generation dual antibody immuno-oncology candidate AM105.

Celltrion’s CT-P51: Will This Keytruda Biosimilar Disrupt the 44 Billion USD Cancer Drug Market?

Celltrion has applied for approval of its biosimilar CT-P51 for the global blockbuster immuno-oncology drug Keytruda (pembrolizumab).

ABL Bio to Launch Global Phase 3 Trial of Gastric Cancer Drug Givastomig This Year at BIO USA

ABL Bio plans a Phase 3 trial for gastric cancer therapy Givastomig, targeting a $2.5 billion market opportunity.

CT-P72/ABP-102: The Next Big Breakthrough in HER2 Cancer Treatment?

Celltrion's CT-P72/ABP-102 shows strong efficacy against HER2 tumors, promising for treating various cancers with reduced toxicity.

AACR 2026 Highlighted Shift Toward Patient-Centered Cancer Drug Development, Foundation Says

Cancer research is evolving towards patient-centered outcomes, integrating data and technology for better treatments, as noted at AACR 2026.

GI-101A: Breakthrough Immuno-Oncology Drug Set for ASCO 2026 Presentation

GI Innovation's GI-101A will be presented at ASCO 2026, highlighting its clinical potential and significance in oncology.

How Celltrion Plans to Cut Biologics Development Costs by 25% Amid FDA Regulation Changes

Celltrion is optimistic about enhanced competitiveness due to eased biosimilar regulations by the FDA, expecting significant cost reductions.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.